JP2006526646A5 - - Google Patents

Download PDF

Info

Publication number
JP2006526646A5
JP2006526646A5 JP2006515010A JP2006515010A JP2006526646A5 JP 2006526646 A5 JP2006526646 A5 JP 2006526646A5 JP 2006515010 A JP2006515010 A JP 2006515010A JP 2006515010 A JP2006515010 A JP 2006515010A JP 2006526646 A5 JP2006526646 A5 JP 2006526646A5
Authority
JP
Japan
Prior art keywords
composition
subject
independently
ring
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006515010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526646A (ja
Filing date
Publication date
Priority claimed from US10/456,942 external-priority patent/US7169750B2/en
Application filed filed Critical
Publication of JP2006526646A publication Critical patent/JP2006526646A/ja
Publication of JP2006526646A5 publication Critical patent/JP2006526646A5/ja
Pending legal-status Critical Current

Links

JP2006515010A 2003-06-05 2004-05-27 前駆細胞/幹細胞を動員するための方法 Pending JP2006526646A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/456,942 US7169750B2 (en) 2001-07-31 2003-06-05 Methods to mobilize progenitor/stem cells
PCT/US2004/016941 WO2005000333A1 (en) 2003-06-05 2004-05-27 Methods to mobilize progenitor/stem cells

Publications (2)

Publication Number Publication Date
JP2006526646A JP2006526646A (ja) 2006-11-24
JP2006526646A5 true JP2006526646A5 (enExample) 2007-08-02

Family

ID=33551303

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006515010A Pending JP2006526646A (ja) 2003-06-05 2004-05-27 前駆細胞/幹細胞を動員するための方法

Country Status (5)

Country Link
US (1) US7169750B2 (enExample)
EP (1) EP1631307A4 (enExample)
JP (1) JP2006526646A (enExample)
CA (1) CA2522048A1 (enExample)
WO (1) WO2005000333A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆/幹細胞を動員するためのケモカインの組み合わせ
US20070043012A1 (en) * 2005-08-19 2007-02-22 Bridger Gary J Methods to enhance chemotherapy
ATE486875T1 (de) 2005-11-10 2010-11-15 Chemocentryx Inc Substituierte chinolone und verwendungsverfahren
AU2006340074A1 (en) * 2006-02-24 2007-09-20 Genzyme Corporation Methods for increasing blood flow and/or promoting tissue regeneration
US7807704B2 (en) 2006-03-30 2010-10-05 Chemocentryx, Inc. Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2
WO2007115232A2 (en) * 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
EP2489728A1 (en) 2006-06-15 2012-08-22 Neostem, Inc Processing procedure for peripheral blood stem cells
MX2009001445A (es) * 2006-08-07 2009-02-18 Genzyme Corp Terapia de combinacion.
EP3011961B1 (en) 2006-12-21 2020-11-11 Biokine Therapeutics LTD. 4f-benzoyl-tn14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation
US7549564B2 (en) * 2007-06-22 2009-06-23 Ethicon Endo-Surgery, Inc. Surgical stapling instrument with an articulating end effector
WO2009154840A2 (en) * 2008-03-27 2009-12-23 Neostem, Inc. Compositions and methods using stem cells in cutaneous wound healing
US8546382B2 (en) * 2009-04-15 2013-10-01 Children's Medical Center Corporation Methods for enhancing hematopoietic progenitor cell engraftment
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103717214A (zh) * 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
AU2013352304C1 (en) 2012-11-29 2018-03-22 Chemocentryx, Inc. CXCR7 antagonists
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
US11312940B2 (en) 2015-08-31 2022-04-26 University Of Louisville Research Foundation, Inc. Progenitor cells and methods for preparing and using the same
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
EP3389720A1 (en) 2015-12-18 2018-10-24 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
CA3014530A1 (en) 2016-02-23 2017-08-31 Biolinerx Ltd. Methods of treating acute myeloid leukemia
EP3423568A4 (en) 2016-03-04 2019-11-13 University Of Louisville Research Foundation, Inc. METHOD AND COMPOSITIONS FOR EX-VIVO REPRODUCTION OF VERY SMALL EMBRYONAL STEM CELLS (VSELS)
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JP6994767B2 (ja) 2016-06-21 2022-01-14 エックス4 ファーマシューティカルズ, インコーポレイテッド Cxcr4阻害剤およびその使用
EP3808748B1 (en) 2016-06-21 2026-05-20 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
IL275077B2 (en) * 2017-12-06 2025-02-01 Magenta Therapeutics Inc Dosing regimens for mobilization of hematopoietic stem and progenitor cells.
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
SG11202105889YA (en) 2018-12-12 2021-07-29 Chemocentryx Inc Cxcr7 inhibitors for the treatment of cancer
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
EP4326257A4 (en) 2021-04-19 2025-03-12 ChemoCentryx, Inc. AZETIDINYLACETAMIDES AS CXCR7 INHIBITORS
WO2025224720A1 (en) 2024-04-24 2025-10-30 Biolinerx Ltd. Methods of selecting treatment regimen against solid tumors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6365583B1 (en) 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
IL145401A0 (en) 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
EP1244648B1 (en) 1999-12-17 2009-04-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds
DE60103052T2 (de) 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
EP2324839B1 (en) * 2000-06-05 2017-08-09 The Trustees of Columbia University in the City of New York Granulocyte-colony-stimulating-factor (g-csf) for use in the treatment of myocardial infarct
KR20030034184A (ko) 2000-09-15 2003-05-01 아노르메드 인코포레이티드 케모킨 수용체 결합 헤테로사이클릭 화합물
RU2289581C2 (ru) 2000-09-15 2006-12-20 Анормед, Инк. Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
NZ524421A (en) 2000-09-15 2005-02-25 Anormed Inc Chemokine receptor binding heterocyclic compounds
ES2320323T3 (es) 2000-09-29 2009-05-21 Anormed Inc. Procedimiento para la preparacion de poliamidas ciclicas con proteccion n-1 que contienen atomos de nitrogeno en forma de anillo n, y producto asi obtenido.
CA2431611A1 (en) 2001-01-23 2002-08-01 P&G-Clairol, Inc. Primary intermediates for oxidative coloration of hair
CN102302493B (zh) * 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法

Similar Documents

Publication Publication Date Title
RU2348617C2 (ru) Производные 2-пиридона в качестве ингибиторов эластазы нейтрофилов и их применение
JP2004518723A5 (enExample)
RU2006132071A (ru) Производные антраниловой кислоты, способы их получения и применение
JP2007502864A5 (enExample)
JP2005508336A5 (enExample)
RU2008119842A (ru) Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1
JP2009532453A5 (enExample)
JP2010501003A5 (enExample)
JP2006501201A5 (enExample)
JP2011513305A5 (enExample)
JP2004516314A5 (enExample)
JP2008504292A5 (enExample)
JP2008510828A5 (enExample)
JP2010524947A5 (enExample)
DK1755590T3 (da) Kombination af glycopyrrolat og en beta2-adrenoceptoragonist
JP2009530392A5 (enExample)
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
RU2394031C2 (ru) Соли четвертичного аммония в качестве антагонистов м3
JP2015528814A5 (enExample)
RU2006130000A (ru) Органические соединения
JP2008513485A5 (enExample)
JP2006503805A5 (enExample)
JP2010513441A5 (enExample)
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств